secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001437749-23-006898
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AcelRx sells DSUVIA/DZUVEO assets to Vertical Pharma for up to $116.5M milestones plus royalties
--------------------------------------------------------------------------------

- AcelRx to sell DSUVIA/DZUVEO sufentanil tablet to Vertical Pharma; gets up to $116.5M in sales milestones and 15% net sales royalty.
- 75% of DoD net sales under marketing agreement; rights revert if Buyer fails to commercialize by July 1, 2023.
- Aguettant amendments: EUR 1.5M payment to AcelRx, termination of sales milestones, and supply restructuring.
- Terminates Catalent site readiness and commercial supply agreements; equipment to be removed from Catalent's site.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774923006898/0001437749-23-006898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774923006898/acrx20230315_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-006898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer